Table 1 Relative risk (RR) for selected cancers within the first year of follow-up among patients previously hospitalised for herpes zoster; follow-up started 2 months after the date of discharge with herpes zoster

From: The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study

 

Observed

RR

95% CIa

All malignant neoplasms

188

1.3

1.1–1.5

Haematological cancers

29

3.4

2.3–4.9

Non-Hodgkin's lymphomab

11

3.8

1.9–6.7

Hodgkin's lymphoma

0

—

—

Multiple myeloma

8

4.8

2.1–9.4

Leukaemia

10

2.8

1.3–5.1

Immune-related cancers

32

1.1

0.8–1.6

Liver

3

1.5

0.4–6.0

Cervix

1

0.5

0.01–2.5

Nonmelanoma skin cancer

24

1.1

0.7–1.7

Malignant melanoma

1

0.5

0.01–2.5

Sarcomac

3

2.7

0.6–7.8

All other sites d

127

1.2

1.0–1.4

Brain

0

—

—

Oesophagus

2

1.3

0.2–5.4

Stomach

6

1.1

0.4–2.3

Colon

12

0.8

0.4–1.4

Rectum

7

1.0

0.4–2.0

Pancreas

6

1.3

0.5–2.7

Lung

22

1.4

0.9–2.2

Breast

12

0.8

0.4–1.4

Corpus uteri

3

0.9

0.2–2.6

Ovary

7

2.3

0.9–4.8

Prostate

14

1.4

0.8–2.4

Kidney

6

1.7

0.6–3.8

Bladder

12

1.4

0.8–2.5

  1. aCI denotes confidence interval.
  2. bNon-Hodgkin's lymphoma is also classified as an immune-related cancer.
  3. cAmong sarcomas, only Kaposi's sarcoma is regarded as an immune-related cancer.
  4. dOnly selected sites are specified.
Back to article page